- Home
- About Us
- Our Products
- Investors
- News
- New Product Pipeline
- Contact Us
Pharmaxis is collaborating with distribution partners around the world to provide Bronchitol® (inhaled dry powder mannitol) via named patient access programs to people suffering from Cystic Fibrosis.
Pharmaxis is also able to provide Bronchitol® (inhaled dry powder mannitol) via named patient access programs for patients with bronchiectasis who have participated in Pharmaxis’ B-301 or B-305 clinical trials. At this time, however, no other bronchiectasis patients are being accepted into the program. Results from the current bronchiectasis study are expected in Q1/Q2 2013 after which we will review our named patient program for bronchiectasis patients based on the findings of the study.
A named patient access program is a mechanism that permits the supply of an unlicensed product to a specific healthcare professional for the treatment of an individual patient. Each country has its own regulations that provide a mechanism to allow access to patients who need these medicinal products. The exact requirements for use vary from country to country.
For Australia, New Zealand or USA:
Healthcare professionals in Australia, New Zealand or USA may contact Pharmaxis for further information about access to Bronchitol for named patient use:
Pharmaxis Medical Information
Phone: +61 2 9454 7226
Email: med.info@pharmaxis.com.au
For the Rest of the World:
Healthcare professionals from the rest of the world may also be able to obtain Bronchitol via a named patient program. For further information please contact:
Clinigen Pharma Limited, UK
Tel: +44 (0) 1283 494 340
Fax: +44 (0) 1283 494 341
Email: customer.services@clinigen.co.uk
Please note that Pharmaxis are not able to provide advice on the suitability of Bronchitol for individual patients. Patients wishing to know more about Bronchitol should discuss with their doctor the most suitable treatment for them.